Ultragenyx Pharmaceutical (RARE) to Release Earnings on Thursday

Ultragenyx Pharmaceutical (NASDAQ:RARE) is anticipated to release its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect Ultragenyx Pharmaceutical to post earnings of ($1.30) per share and revenue of $199.5960 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 12, 2026 at 5:00 PM ET.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock opened at $24.20 on Wednesday. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -4.07 and a beta of 0.16. The stock’s 50-day moving average is $27.74 and its 200-day moving average is $29.87. Ultragenyx Pharmaceutical has a one year low of $18.41 and a one year high of $46.27.

Analysts Set New Price Targets

RARE has been the topic of several research reports. Guggenheim cut their target price on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research note on Monday, January 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 21st. Barclays reduced their target price on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, November 24th. Truist Financial decreased their target price on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Finally, Jefferies Financial Group cut their price target on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a research report on Tuesday, December 30th. Sixteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $72.29.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Long‑term efficacy reported for Ultragenyx’s gene therapy in two Sanfilippo studies, which supports the commercial and clinical value of the company’s rare‑disease pipeline and is a clear fundamental positive for future revenue potential. Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies
• Neutral Sentiment: Trading remains below recent averages (about 1.2M shares vs. a ~2.7M average) and the stock sits below its 50‑ and 200‑day moving averages, indicating limited participation and scope for higher volatility until catalysts crystallize.
• Negative Sentiment: Multiple plaintiff law firms have announced or are pursuing a securities‑fraud class action covering purchases from Aug. 3, 2023 through Dec. 26, 2025, and are soliciting lead‑plaintiff candidates (lead‑plaintiff deadline cited as April 6, 2026). Litigation risk can create overhang, increase legal costs, and weigh on investor sentiment. RARE Investors: Kessler Topaz Meltzer & Check, LLP Reminds Investors of April 6, 2026 Deadline
• Negative Sentiment: Unusual options flow: investors purchased a large block of put options (5,997 contracts, ~240% above average put volume), signaling short‑term bearish positioning or hedging that can amplify downside pressure if those trades reflect broader negative sentiment.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 3,081 shares of Ultragenyx Pharmaceutical stock in a transaction dated Wednesday, December 10th. The shares were sold at an average price of $36.38, for a total value of $112,086.78. Following the completion of the transaction, the chief financial officer owned 95,146 shares of the company’s stock, valued at $3,461,411.48. This trade represents a 3.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last ninety days, insiders have sold 6,227 shares of company stock valued at $187,126. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Natixis Advisors LLC raised its position in shares of Ultragenyx Pharmaceutical by 7.7% in the fourth quarter. Natixis Advisors LLC now owns 21,077 shares of the biopharmaceutical company’s stock valued at $485,000 after purchasing an additional 1,498 shares during the period. Geode Capital Management LLC grew its stake in Ultragenyx Pharmaceutical by 16.3% in the 4th quarter. Geode Capital Management LLC now owns 1,838,208 shares of the biopharmaceutical company’s stock valued at $42,287,000 after buying an additional 257,701 shares during the last quarter. Danske Bank A S acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $39,000. Jacobs Levy Equity Management Inc. raised its holdings in Ultragenyx Pharmaceutical by 614.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after acquiring an additional 1,864,164 shares during the period. Finally, CANADA LIFE ASSURANCE Co raised its holdings in Ultragenyx Pharmaceutical by 2.0% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 26,932 shares of the biopharmaceutical company’s stock valued at $817,000 after acquiring an additional 534 shares during the period. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.